Effect of Routine Vaccination on Aluminum and Essential Element Levels in Preterm Infants

Parenteral feedings containing more than 4 to 5 µg/kg/d of aluminum have been shown to result in neurodevelopmental delay in preterm infants.¹ However, an infant at the 2-month checkup receives multiple aluminum-containing vaccines that in combination may have as high as 1225 µg of intramuscular aluminum; this is a much higher intramuscular aluminum dose than the safely recommended intravenous aluminum dose.² Our first objective was to measure prevaccine and postvaccine levels of aluminum in preterm infants, a population at higher risk of aluminum neurotoxic effects. Our second objective was to measure prevaccine and postvaccine levels of essential elements (EE). Inflammation from trauma can cause declines in serum levels of specific EE such as zinc and selenium^3-5; there may be similar EE perturbations secondary to vaccination-induced inflammation.

After institutional review board approval and parental consent, 15 preterm infants scheduled for routine 2-month vaccinations while still hospitalized were recruited in the Sparrow Hospital neonatal intensive care unit in East Lansing, Michigan. One day prior to scheduled vaccination, 0.25-mL blood and 12-hour urine collections were obtained. Prevnar 13, PedvaxHIB, and Pediarix vaccines were administered, in total containing 1200 µg of aluminum, as determined by company literature and confirmed by testing a set of these vaccines in our laboratory. One day postvaccination, 0.25-mL blood and 12-hour urine collections were obtained. Aluminum and EE concentrations were quantified by inductively coupled plasma mass spectrometry in serum and urine. Urine data were normalized using creatinine concentration. Two-tailed P values <.05 on paired t tests (SAS software; SAS Institute Inc) were considered significant.

No significant change in levels of urinary or serum aluminum were seen after vaccination (Table). Significant declines were noted postvaccination in serum iron (58.1%), manganese (25.9%), selenium (9.5%), and zinc (36.4%) levels, as was a significant increase in serum copper level (8.0%). A rise in selenium level was the only significant urine change. No significant postvaccine urinary or serum level changes were noted for phosphorus, sulfur, potassium, cobalt, nickel, molybdenum, nickel, or sodium. All participants had normal serum creatinine levels.

We were reassured to find no significant postvaccine rise in serum aluminum level after vaccination of preterm infants with vaccines containing a total of 1200 µg of aluminum. The average study infant weighed 2200 g at vaccination and thus received about 545 µg/kg of intramuscular aluminum. Thus far, infant aluminum-adjuvant dosage safety has relied on animal-to-human extrapolations⁶ and modeling of infant pharmacokinetics based on extrapolation from adult pharmacokinetic data to infant glomerular filtration rates.⁷ We know of no study prior assessing actual aluminum blood level responses to vaccination in human infants.

Our study is small (N = 15), but one of the key studies for examining the postvaccine rise in aluminum blood levels is a study of only 6 rabbits.⁶ That study showed that postvaccination serum aluminum levels rose 1%, peaking within 24 hours of vaccination. We thus chose 24 hours as our postvaccine measurement point.⁶

We observed a significant decline of serum levels of iron, manganese, zinc, and selenium and a significant increase in copper level (a marker of inflammation) on the day after vaccination. These same EE have been described as declining after inflammation from trauma or burns.^3-5 Of the EE that are not known to be associated with inflammation-induced perturbations (ie, sodium and potassium), we found stability of these levels after vaccination.

None of our participants had changes in nutrition type, medications, and/or blood transfusions during the course of the study. Therefore, it is reasonable to assume that the EE changes were a result of vaccination. Because of the aforementioned stability of aluminum-influencing factors (ie, nutrition and medications), postvaccine aluminum changes, if they were to have occurred, could have been attributed to vaccination dosage.

Sequestration of certain EE into tissues with a subsequent reduction of serum levels of corresponding EE is an important component of the innate immune system.⁸ This immune response has likely evolved as a host defense mechanism to deprive microbial organisms of their nutrients.⁸ While this vaccine-induced homeostatic shift in EE levels has not previously been described in humans, it has been documented in horses. After vaccination of horses, iron and other EE become temporarily sequestered within hepatocytes and other cell types.^9,10 As has also been found in other studies of EE after inflammation,^3-5 we found a significant rise in postvaccine urinary selenium levels, suggesting that selenium is at least partially excreted, rather than completely sequestered like other micronutrients for which there was no postvaccination urinary rise.

Limitations of our study include its small sample size and single postvaccine measurement, as well as the absence of markers of inflammation to help quantify the inflammatory response. However, because trace elements play important roles in neurodevelopment and the immune system, the effect of vaccination on EE should be investigated in more detail.

Corresponding Author: Tammy Z. Movsas, MD, MPH, Midland County Department of Public Health, 220 W Ellsworth, Midland, MI 48640 (tmovsas@gmail.com).

Published Online: July 15, 2013. doi:10.1001/jamapediatrics.2013.108.

Author Contributions: All authors have seen and approved the submission of this manuscript and take full responsibility for it.

Study concept and design: Movsas, Paneth, Gewolb.

Acquisition of data: Rumbeiha, Zyskowski, Gewolb.

Analysis and interpretation of data: Movsas, Paneth, Gewolb.

Drafting of the manuscript: Movsas, Paneth, Zyskowski.

Critical revision of the manuscript for important intellectual content: Movsas, Paneth, Rumbeiha, Gewolb.

Statistical analysis: Movsas, Paneth, Gewolb.

Administrative, technical, and material support: Movsas, Paneth, Zyskowski, Gewolb.

Study supervision: Movsas, Paneth, Gewolb.

Conflict of Interest Disclosures: None reported.

Funding/Support: This project was undertaken by Dr Movsas while she was a postdoctoral fellow in the National Institutes of Health T32 Training Program in Perinatal Epidemiology at Michigan State University, grant 2T32HD046377.